Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression

Sharpley Hsieh; Jashelle Caga; Felicity V. C. Leslie; Marlene Shibata; Naomi Daveson; David Foxe; Eleanor Ramsey; Patricia Lillo; Rebekah M. Ahmed; Emma Devenney; James R. Burrell; John R. Hodges; Matthew C. Kiernan; Eneida Mioshi

doi:10.1177/0891988715598232

Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression

Sharpley Hsieh, Jashelle Caga, Felicity V. C. Leslie, Marlene Shibata, Naomi Daveson, David Foxe, Eleanor Ramsey, Patricia Lillo, Rebekah M. Ahmed, Emma Devenney, James R. Burrell, John R. Hodges, Matthew C. Kiernan, Eneida Mioshi

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Brief screening tools that detect and differentiate patients with amyotrophic lateral sclerosis and frontotemporal dementia (ALSFTD) from those more subtle cognitive or behavioral symptoms (ALS plus) and motor symptoms only (ALS pure) is pertinent in a clinical setting. The utility of 2 validated and data-driven tests (Mini-Addenbrooke’s Cognitive Examination [M-ACE] and Motor Neuron Disease Behavioral Scale [MiND-B]) was investigated in 70 ALS patients (24 ALSFTD, 19 ALS plus, and 27 ALS pure). More than 90% of patients with ALSFTD scored at or below the cutoff on the M-ACE, whereas this was seen in only about 20% of ALS patients without dementia. The MiND-B differentiated between ALS pure and ALS plus diagnostic categories. Rasch modeling of M-ACE and MiND-B items revealed early cognitive (fluency, memory recall) and behavioral (apathy) symptoms in ALSFTD. The combined use of the M-ACE and MiND-B detects patients with ALSFTD, differentiates along the ALS continuum, and offers insight into the progression of nonmotor symptomatology in ALSFTD.

Original language	English
Pages (from-to)	3-10
Number of pages	8
Journal	Journal of Geriatric Psychiatry and Neurology
Volume	29
Issue number	1
Early online date	6 Aug 2015
DOIs	https://doi.org/10.1177/0891988715598232
Publication status	Published - Jan 2016

Keywords

amyotrophic lateral sclerosis
frontotemporal dementia
cognitive screening
behavioral disturbance

Access to Document

10.1177/0891988715598232

http://jgp.sagepub.com/cgi/doi/10.1177/0891988715598232

Cite this

Hsieh, S., Caga, J., Leslie, F. V. C., Shibata, M., Daveson, N., Foxe, D., Ramsey, E., Lillo, P., Ahmed, R. M., Devenney, E., Burrell, J. R., Hodges, J. R., Kiernan, M. C., & Mioshi, E. (2016). Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression. Journal of Geriatric Psychiatry and Neurology, 29(1), 3-10. https://doi.org/10.1177/0891988715598232

@article{6e12c0ff0a14444da98105ae1c6ffeb3,

title = "Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression",

abstract = "Brief screening tools that detect and differentiate patients with amyotrophic lateral sclerosis and frontotemporal dementia (ALSFTD) from those more subtle cognitive or behavioral symptoms (ALS plus) and motor symptoms only (ALS pure) is pertinent in a clinical setting. The utility of 2 validated and data-driven tests (Mini-Addenbrooke{\textquoteright}s Cognitive Examination [M-ACE] and Motor Neuron Disease Behavioral Scale [MiND-B]) was investigated in 70 ALS patients (24 ALSFTD, 19 ALS plus, and 27 ALS pure). More than 90% of patients with ALSFTD scored at or below the cutoff on the M-ACE, whereas this was seen in only about 20% of ALS patients without dementia. The MiND-B differentiated between ALS pure and ALS plus diagnostic categories. Rasch modeling of M-ACE and MiND-B items revealed early cognitive (fluency, memory recall) and behavioral (apathy) symptoms in ALSFTD. The combined use of the M-ACE and MiND-B detects patients with ALSFTD, differentiates along the ALS continuum, and offers insight into the progression of nonmotor symptomatology in ALSFTD. ",

keywords = "amyotrophic lateral sclerosis, frontotemporal dementia, cognitive screening, behavioral disturbance",

author = "Sharpley Hsieh and Jashelle Caga and Leslie, {Felicity V. C.} and Marlene Shibata and Naomi Daveson and David Foxe and Eleanor Ramsey and Patricia Lillo and Ahmed, {Rebekah M.} and Emma Devenney and Burrell, {James R.} and Hodges, {John R.} and Kiernan, {Matthew C.} and Eneida Mioshi",

year = "2016",

month = jan,

doi = "10.1177/0891988715598232",

language = "English",

volume = "29",

pages = "3--10",

journal = "Journal of Geriatric Psychiatry and Neurology",

issn = "0891-9887",

publisher = "Sage Publications",

number = "1",

}

Hsieh, S, Caga, J, Leslie, FVC, Shibata, M, Daveson, N, Foxe, D, Ramsey, E, Lillo, P, Ahmed, RM, Devenney, E, Burrell, JR, Hodges, JR, Kiernan, MC & Mioshi, E 2016, 'Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression', Journal of Geriatric Psychiatry and Neurology, vol. 29, no. 1, pp. 3-10. https://doi.org/10.1177/0891988715598232

TY - JOUR

T1 - Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression

AU - Hsieh, Sharpley

AU - Caga, Jashelle

AU - Leslie, Felicity V. C.

AU - Shibata, Marlene

AU - Daveson, Naomi

AU - Foxe, David

AU - Ramsey, Eleanor

AU - Lillo, Patricia

AU - Ahmed, Rebekah M.

AU - Devenney, Emma

AU - Burrell, James R.

AU - Hodges, John R.

AU - Kiernan, Matthew C.

AU - Mioshi, Eneida

PY - 2016/1

Y1 - 2016/1

N2 - Brief screening tools that detect and differentiate patients with amyotrophic lateral sclerosis and frontotemporal dementia (ALSFTD) from those more subtle cognitive or behavioral symptoms (ALS plus) and motor symptoms only (ALS pure) is pertinent in a clinical setting. The utility of 2 validated and data-driven tests (Mini-Addenbrooke’s Cognitive Examination [M-ACE] and Motor Neuron Disease Behavioral Scale [MiND-B]) was investigated in 70 ALS patients (24 ALSFTD, 19 ALS plus, and 27 ALS pure). More than 90% of patients with ALSFTD scored at or below the cutoff on the M-ACE, whereas this was seen in only about 20% of ALS patients without dementia. The MiND-B differentiated between ALS pure and ALS plus diagnostic categories. Rasch modeling of M-ACE and MiND-B items revealed early cognitive (fluency, memory recall) and behavioral (apathy) symptoms in ALSFTD. The combined use of the M-ACE and MiND-B detects patients with ALSFTD, differentiates along the ALS continuum, and offers insight into the progression of nonmotor symptomatology in ALSFTD.

AB - Brief screening tools that detect and differentiate patients with amyotrophic lateral sclerosis and frontotemporal dementia (ALSFTD) from those more subtle cognitive or behavioral symptoms (ALS plus) and motor symptoms only (ALS pure) is pertinent in a clinical setting. The utility of 2 validated and data-driven tests (Mini-Addenbrooke’s Cognitive Examination [M-ACE] and Motor Neuron Disease Behavioral Scale [MiND-B]) was investigated in 70 ALS patients (24 ALSFTD, 19 ALS plus, and 27 ALS pure). More than 90% of patients with ALSFTD scored at or below the cutoff on the M-ACE, whereas this was seen in only about 20% of ALS patients without dementia. The MiND-B differentiated between ALS pure and ALS plus diagnostic categories. Rasch modeling of M-ACE and MiND-B items revealed early cognitive (fluency, memory recall) and behavioral (apathy) symptoms in ALSFTD. The combined use of the M-ACE and MiND-B detects patients with ALSFTD, differentiates along the ALS continuum, and offers insight into the progression of nonmotor symptomatology in ALSFTD.

KW - amyotrophic lateral sclerosis

KW - frontotemporal dementia

KW - cognitive screening

KW - behavioral disturbance

U2 - 10.1177/0891988715598232

DO - 10.1177/0891988715598232

M3 - Article

VL - 29

SP - 3

EP - 10

JO - Journal of Geriatric Psychiatry and Neurology

JF - Journal of Geriatric Psychiatry and Neurology

SN - 0891-9887

IS - 1

ER -